Increased microparticle levels in middle-aged and elderly patients with insomnia may be involved in the pathogenesis

Bin Xu1,2, Li Ma1,3, Ning Zhang4

  • 1Department of General Practice, School of General Practice and Continuing Education, Capital Medical University, Beijing, China.

Abstract

Insights

Insomnia is linked to higher levels of microparticles (MPs) associated with endothelial injury and leukocyte activation, suggesting increased atherosclerosis risk. Chronic insomnia shows even higher levels of these MPs, indicating potential disease progression.

Area of Science:

  • Cardiovascular Research
  • Sleep Medicine
  • Biomarkers

Background:

  • Insomnia may promote arteriosclerosis by affecting vascular factors.
  • Microparticles (MPs) are implicated in atherosclerosis pathogenesis.
  • Limited research exists on MP levels in sleep disorders.

Purpose of the Study:

  • To measure endothelial microparticles (EMPs), platelet microparticles (PMPs), and leukocyte-derived microparticles (LMPs) in middle-aged and elderly patients with and without insomnia.
  • To investigate the association between insomnia, its subtypes (acute vs. chronic), and MP levels.

Main Methods:

  • Enrolled 30 insomnia patients (16 chronic, 14 acute) and 18 controls.
  • Measured EMPs (CD31+, CD62E+), PMPs (CD41a+, CD42a+), and granulocyte-derived MPs (CD11a+) using flow cytometry.
  • Defined MP reference and size gates using microspheres.

Main Results:

  • Significantly higher levels of CD31+ MPs, CD62E+ MPs, and CD11a+ MPs were observed in the insomnia group compared to the non-insomnia group (P<0.05).
  • Chronic insomnia patients exhibited significantly higher levels of CD31+ MPs and CD11a+ MPs compared to those with acute insomnia (P<0.001).

Conclusions:

  • CD31+ EMPs may contribute to atherosclerosis progression in insomnia patients via apoptosis and endothelial injury.
  • Elevated CD11a+ LMPs with persistent insomnia suggest a potential indicator of ongoing atherosclerosis progression.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
147
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
174
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
154
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
147
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
296
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
193